July - September 2019, Volume 15, Issue 3

Dehelean L, Romosan AM, Manea MM, Papava I, Andor M, Romosan RS

The Metabolic Syndrome in Outpatients with Psychosis: a Comparative Study Between Long Acting Injectable Olanzapine and Risperidone

Acta Endo (Buc) 2019, 15 (3): 342-348
doi: 10.4183/aeb.2019.342

Context. Literature shows that patients taking antipsychotic medication risk developing metabolic complications. Objective. The study aims to compare the presence of the metabolic syndrome (MS) and its components in outpatients treated with long acting injectable (LAI) olanzapine and risperidone. Design. A double-center study was performed on outpatients with psychosis, which were divided into two samples: one treated with olanzapine and another with risperidone. Subjects and Methods. The following data were analyzed: age, gender, severity of psychiatric symptoms, blood pressure, waist circumference, fasting blood glucose, lipid profile, tobacco use, medication, and time intervals related to psychosis duration (pre-LAI and LAI treatment). Results. The study included 77 patients with schizophrenia and schizoaffective disorder. MS was present in 45 (58.4%) patients. Subjects with MS and abdominal obesity had higher durations of psychosis and of LAI treatment. Patients with hypertension had a higher pre- LAI treatment interval. Risperidone was associated with higher rates of hypertension and higher values of abdominal circumference than olanzapine. Conclusions. The presence of MS is related to the duration of the psychosis and the time spent on LAI treatment with no differences between olanzapine and risperidone. Hypertension may be a consequence of age, disorder induced stress, or of treatment with risperidone.

Keywords: metabolic syndrome, long acting injectable, olanzapine, risperidone

Correspondence: Ana-Maria Romosan MD, “Victor Babes”University of Medicine and Pharmacy, 2 Eftimie Murgu Sq, Timisoara, 300041, Romania, E-mail: ana.romosan@gmail.com